Comparing U.S. drug prices to other countries: A more nuanced view

GUEST COLUMN, Melanie Whittington, Center for Pharmacoeconomics
President Trump recently signed a new executive order advancing a "most favored nation" (MFN) approach to drug pricing. The policy would link U.S. prices for certain medicines to those paid in other high-income countries — an idea that's gaining traction as frustration over higher drug prices builds at home.
At first glance, MFN may seem like a desirable and reasonable step: if Germany or Japan can pay less for a drug, why can't we? But comparisons like these, while politically appealing, are far more complicated than they appear.